Short answer: PT-141 is the research name for bremelanotide, a synthetic peptide that works on melanocortin receptors in the brain — the pathways behind desire, not blood flow. It is the only compound in this catalog with a completed pharmaceutical development program behind it. Here it appears in one product: the PT-141+ strip.
PT-141 is the easiest peptide on this site to describe accurately, because a real drug-development program did the characterization work — and the easiest to describe lazily, because injectable data gets quietly borrowed to sell formats that were never tested. This page walks the honest middle.
Where PT-141 came from
PT-141 is bremelanotide, a synthetic cyclic seven-amino-acid peptide derived from research on Melanotan II, a lab-made analog of alpha-MSH. During early pigmentation research, investigators noticed effects on sexual response and split the program; the desire branch became bremelanotide. That origin story matters: the compound was discovered doing what it's now known for.
In 2019, after two identically designed phase 3 randomized, double-blind, placebo-controlled trials (the RECONNECT program, roughly 1,200 participants; PMID 31599840) and a 52-week open-label extension (PMID 31599847), the FDA approved bremelanotide as a subcutaneous injection (brand name Vyleesi) for a specific diagnosed medical indication [published human data]. This page won't go further into indication territory — that's between patients and their clinicians — but the existence of that approval is what sets PT-141 apart from everything else in the peptide world.
How it's thought to work
Most intimacy pharmacology acts on blood flow. PT-141 acts upstream, on the brain's melanocortin receptors — principally MC4R — in pathways involved in desire and motivation (Edinoff et al., 2022, PMC8788464) [published human data — mechanism]. It's a melanocortin agonist, not a hormone: it contains no estrogen, testosterone, or anything like them. Users commonly report that it feels different in kind — interest and anticipation rather than mechanics [attributed user reports]. Brand copy describes PT-141+ as helping you "feel more connected, confident, and responsive" [brand claim — unverified].
It's also not selective — bremelanotide touches MC1R through MC5R to varying degrees, which explains its best-known effects (nausea centrally; skin darkening via the pigmentation receptor). Good to know before anyone tells you it's side-effect-free.
What the research has explored
- A defined mechanism: melanocortin receptor agonism, principally MC4R, acting on central desire pathways
[published human data — mechanism]. - Two phase 3 RCTs with statistically significant improvements on the program's co-primary desire and distress endpoints versus placebo; a secondary endpoint did not reach significance
[published human data — injectable]. - A safety database spanning the phase 3 program plus a 52-week open-label extension
[published human data — injectable]. - The injectable's most common adverse events in phase 3: nausea (40.0% vs 1.3% placebo), flushing (20.3%), injection-site reactions (13.2%), headache (11.3%) — plus transient blood-pressure increases, which is why the approved drug is contraindicated in uncontrolled hypertension and known cardiovascular disease
[published human data — injectable format only].
Those receptor-mediated effects aren't route-specific, so they're fair context for any format — and the cardiovascular note is real advice: if you have blood-pressure or heart concerns, talk to a physician first regardless of format.
Formats: injection legacy, strip present
Every human data point above comes from subcutaneous injection and earlier intranasal work. The strip format answers the lived-experience question instead: no needle moment, no fridge, no planning ritual — a mint strip that dissolves in about a minute. Whether a strip delivers enough bremelanotide through the oral mucosa to matter is the open question, and it's the same framework we apply across the catalog on our sublingual delivery science pillar.
The honest context
One bounded passage, because this category attracts more borrowed credibility than any other: no published study has ever measured bremelanotide absorption, effect, or safety from an oral dissolving film, and the approved drug's trial program tested bremelanotide alone — not a blend, not a strip. If you're experiencing persistent, distressing changes in desire, that's a medical conversation worth having with a licensed clinician, who can evaluate the causes and prescribe what actually has trials behind it. A supplement strip is not a substitute. Adults 18+ only; not while pregnant or nursing.
Where PT-141 appears in our catalog
PT-141 appears in one product: Intimacy — PT-141+, an oral dissolving strip containing, per the printed Supplement Facts panel, PT-141 1 mg, Oxytocin 25 mcg, and Aminophenpyrrole 20 mg — 10 mint strips per box. It's a three-part blend, not PT-141 alone. A few things we state rather than smooth over:
- Retail and wholesale. PT-141+ is available at open checkout like the rest of the line, with case-pack pricing for clinics through the wholesale program. The PT-141+ sublingual strips page carries the current panel.
- The COA tests two of three actives. Per our product data, the lot's Certificate of Analysis verifies PT-141 and Oxytocin only; the third active is not assayed. We report the label, not vouch for it
[brand claim — unverified]. - A packaging typo, flagged. Per our product data, the box prints "Oxytoxin"; the COA for the same lot spells "Oxytocin" correctly. We use the correct spelling and have raised the misprint with the brand. Our safety and sourcing pillar shows how to read these documents yourself.
The strips are sold under the InstaMed brand (Salt Lake City/Draper, Utah); we sell them as an authorized reseller.
The bottom line
PT-141 has the strongest pharmaceutical pedigree in the entire peptide category — a real mechanism on real desire pathways, a real approval behind the injectable, and a genuinely different feel that users love. PT-141+ wraps that molecule with oxytocin in a discreet mint strip built for connection and confidence. If you're a practitioner looking at the intimacy category, this is the serious candidate — with the verification gaps stated up front.
---
Explore this cluster
The rest of the PT-141 file — the clinical record, the label's safety numbers, how it differs from the ED drugs, and what is and is not established by sex.
- How to Use PT-141: The Lifestyle-First Guide to Timing and Format
- PT-141 Benefits: What the Clinical Research Shows
- PT-141 for Men: Why the Evidence Picture Is Different
- PT-141 for Women: What the Research Is (and Isn't)
- PT-141 vs Viagra and Cialis: How They Actually Differ
- Does Sublingual PT-141 Work? What the Evidence Shows
- PT-141 Side Effects: The FDA Label Numbers, Explained
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.